Ritobegron ethyl clinical trials
How each study uses ritobegron ethyl is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Boehringer Ingelheim (6) · Kissei Pharmaceutical Co., Ltd. (3)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A prodrug of Ritobegron source
Studies
Open first, then newest update. How each study uses ritobegron ethyl is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259920Written as KUC 7483 CL, immediate release tabletHow we know
- Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259764Written as KUC 7483 CL - single rising doseHow we know
- Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259907Written as KUC 7483 CLHow we know
- Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor OveractivityCompletedPhase 1Boehringer IngelheimNCT02259751Written as KUC 7483 CLHow we know
- Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259933Written as KUC 7483 CLHow we know
- In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02256722Written as KUC 7483 CLHow we know
- A Confirmatory Study of KUC-7483 in Patients With Overactive BladderCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01004315Written as KUC-7483How we know
- Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive BladderWithdrawnPhase 3Kissei Pharmaceutical Co., Ltd.NCT01003405Written as KUC-7483How we know
- A Phase II Study of KUC-7483 in Patients With Overactive BladderCompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT00742833Written as KUC-7483How we know
Codes
What other systems call ritobegron ethyl · ClinicalTrials.gg INT006178
- MeSH (NLM) C576375ritobegron ethylOne source NLM
- UNII (FDA) E89L9L8KFHRITOBEGRON ETHYLConfirmed NLM, Wikidata
- Wikidata Q27277006ritobegron ethylConfirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C576375 | ritobegron ethyl | One source NLM |
| UNII (FDA) | E89L9L8KFH | RITOBEGRON ETHYL | Confirmed NLM, Wikidata |
| Wikidata | Q27277006 | ritobegron ethyl | Confirmed NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.